1. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
- Author
-
Nichole D. Salinas, Sachy Orr-Gonzalez, Brandi Butler, Ouahes T, Dickey Th, Lynn Lambert, Wanhu Tang, and Niraj H. Tolia
- Subjects
chemistry.chemical_classification ,COVID-19 Vaccines ,Multidisciplinary ,biology ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Viral Vaccines ,Vaccine antigen ,Virology ,Antibodies, Neutralizing ,In vitro ,Article ,Amino acid ,Neutralizing epitope ,Immune system ,chemistry ,Spike Glycoprotein, Coronavirus ,biology.protein ,Humans ,sense organs ,Antibody ,Amino Acids ,Neutralizing antibody ,skin and connective tissue diseases - Abstract
The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the primary target of neutralizing antibodies and is a component of almost all vaccine candidates. Here, RBD immunogens were created with stabilizing amino acid changes that improve the neutralizing antibody response, as well as characteristics for production, storage, and distribution. A computational design and in vitro screening platform identified three improved immunogens, each with approximately nine amino acid changes relative to the native RBD sequence and four key changes conserved between immunogens. The changes are adaptable to all vaccine platforms, are compatible with established changes in SARS-CoV-2 vaccines, and are compatible with mutations in emerging variants of concern. The immunogens elicit higher levels of neutralizing antibodies than native RBD, focus the immune response to structured neutralizing epitopes, and have increased production yields and thermostability. Incorporating these variant-independent amino acid changes in next-generation vaccines may enhance the neutralizing antibody response and lead to pan-SARS-CoV-2 protection.
- Published
- 2021